Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.
Non-Hodgkin's lymphoma (NHL) is the sixth most common cancer in the United Kingdom (UK). This analysis assessed the health service costs of patients receiving chemotherapy for indolent follicular NHL based on a retrospective analysis of patient records in the UK. Each patient was followed up for a period of 3 years or until death. The analysis included 181 patients, who received a total of 187 treatment periods. Costs were estimated from the perspective of the UK National Health Service. The study found the cost of providing treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) or fludarabine to patients with indolent follicular NHL to be lower than previously reported.
Hutchinson
Julia
J
Fourth Hurdle Consulting, London, UK. JuliaHutchinson@FourthHurdle.com
Lloyd
Adam
A
Gray
Alastair
A
Gale
Rupert
R
Hancock
Barry
B
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000191:economics*; D003365:Costs and Cost Analysis; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000191:economics; D004317:Doxorubicin / Q000008:administration & dosage / Q000191:economics; D005260:Female; D005500:Follow-Up Studies; D006296:Health Services / Q000191:economics; D006801:Humans; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000191:economics* / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage / Q000191:economics; D012189:Retrospective Studies; D006113:United Kingdom; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics; D014750:Vincristine / Q000008:administration & dosage / Q000191:economics
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine; D011241:Prednisone